Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
2.
2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
4.
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
5.
2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
6.
Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61M 35/00 - Dispositifs pour appliquer des agents, p. ex. des remèdes, sur le corps humain
B05B 11/00 - Appareillages monoblocs tenus à la main dans lesquels l'écoulement du contenu est produit par la force musculaire de l'opérateur au moment de l'utilisation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
Controlled release pharmaceutical dosage forms, methods of making the same, and methods of using the same to treat dermatological conditions are disclosed. A doxycycline formulation that is retained and released in a controlled manner in the upper portion of the gastrointestinal tract. The formulation provides enhanced efficacy and reduced side effects and/or adverse effects when compared to conventional immediate release dosage forms of doxycydine. Although delaying the release of doxycycline has previously been reported to decrease doxycycline's oral bioavailability, it has now been surprisingly found that when administered in a controlled release fashion, the relative oral bioavailability when compared to immediate release formulation of doxycycline was more than about 80% and in certain embodiments, more than about 90% orally bioavailable.
The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.
Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
12.
HIGH DOSAGE TOPICAL METRONIDAZOLE GEL FORMULATIONS
The present disclosure provides aqueous-based gel formulations of metronidazole useful for a variety of purposes, including topical application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with rosacea.
Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
This disclosure is directed to the use of sequentially applied topical therapy with a lower dosage strength imiquimod composition and photodynamic therapy for treating actinic keratosis, wherein the photodynamic therapy is administered subsequent to the topical therapy with the imiquimod composition. In some embodiments, the imiquimod composition comprises from about 1% (w/w) to about 4.25% (w/w) imiquimod.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61Q 19/00 - Préparations pour les soins de la peau
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
16.
COMBINATION THERAPY WITH LOW DOSAGE STRENGTH IMIQUIMOD AND PHOTODYNAMIC THERAPY TO TREAT ACTINIC KERATOSIS
This disclosure is directed to the use of complementary or combination photodynamic therapy and topical therapy with a lower dosage strength imiquimod formulation for treating actinic keratosis.
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino
A61K 8/44 - Acides aminocarboxyliques ou leurs dérivés, p. ex. acides aminocarboxyliques contenant du soufreLeurs sels, esters ou dérivés N-acylés
A61K 8/40 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant de l'azote
The invention provides compositions containing a retinoid and a lincosamide antibiotic for the treatment or amelioration of rosacea. The invention also provides methods for treating or ameliorating rosacea using compositions containing a retinoid and a lincosamide antibiotic.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
18.
HIGH DOSAGE MUCOADHESIVE METRONIDAZOLE AQUEOUS-BASED GEL FORMULATIONS THEIR USE TO TREAT BACTERIAL VAGINOSIS
The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
This disclosure relates to mid-face aesthetic scales and related methods for evaluating fullness in a mid-face area of a human patient's face. In exemplary embodiments, the mid-face area is defined as medial to the maxillary prominence, lateral to the medial canthus, inferior to the maxillary prominence, superior to the plane of nasal alae, and lateral to the nose. An exemplary method for evaluating fullness in a mid-face area of a human patient's face comprises visually comparing a plurality of views of the patient's mid-face against a mid-face scale, and assigning a grade from the scale to the patient's mid-face based on the visual comparison.
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
23.
Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).
G01F 11/00 - Appareils qu'il faut actionner de l'extérieur, adaptés à chaque opération répétée et identique, pour mesurer et séparer le volume prédéterminé d'un fluide ou d'un matériau solide fluent à partir d'une alimentation ou d'un récipient sans tenir compte du poids, et pour fournir ce volume
A61M 35/00 - Dispositifs pour appliquer des agents, p. ex. des remèdes, sur le corps humain
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
B05B 11/00 - Appareillages monoblocs tenus à la main dans lesquels l'écoulement du contenu est produit par la force musculaire de l'opérateur au moment de l'utilisation
24.
PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM
The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation ("pump systems") and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosalassociated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
B67B 5/00 - Application de couvercles protecteurs ou décoratifs sur les fermeturesDispositifs pour fixer les fermetures de bouteilles avec du fil de fer
25.
COMBINATION THERAPY WITH CRYOSURGERY AND LOW DOSAGE STRENGTH IMIQUIMOD TO TREAT ACTINIC KERATOSIS
The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis ("AK"). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion- directed therapy.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1 isobuty 1-1 H-imidazo [4, 5 -c] -quinolin-4-amine or 1 -(2-methylpropyl)- 1 H-imidazo [4,5 -c] quinolin-4-arnme, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
A01N 43/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à six chaînons condensés avec des carbocycles
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
29.
METHODS FOR MEASURING CHANGE IN LIP SIZE AFTER AUGMENTATION
A method for measuring the effect of a medical treatment on the size of lips. The method has the following steps: (a) providing a scale of at least four visual reference images exhibiting varying lip sizes and assigning a unique indicator to each of the at least four visual reference images; (b) visually examining a lip of a human subject to be augmented and selecting one from among of at least four different reference images most closely corresponding in lip size and identifying the corresponding unique indicator; (c) introducing into the lip of the human subject a filler or an implant to augment the size of the lip; (d) visually examining the lip after introduction of the filler or the implant and selecting one of the at least four different reference images most closely corresponding in lip size and identifying the corresponding unique indicator; and (e) comparing the unique indicator of the lip before introduction of the filler or the implant and the unique indicator of the lip after introduction of the filler or the implant to determine if they are different. There is also a method for counseling a human subject undertaking augmentation of lips. There is also a method for developing a scale for measuring differences in lip size in human subjects. There is also a method for determining the amount of filler or implant needed to augment the lips of a human subject.
Topical compositions comprising bimosiamose are provided for treatment of a skin disorder such as psoriasis. In some embodiments, the compositions are formulated as creams and have pH between about 6.0 and 7.5. Methods of manufacturing such compositions are also described.
A01N 43/38 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons condensés avec des carbocycles
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A method for treating acne on the skin. The method has the steps of (a) providing an drapeable or flexible porous article impregnated with an aqueous cleansing composition having a carrier, benzoyl peroxide, and one or more cleansing agents; (b) contacting an area of the skin affected by acne with the porous article such that the skin is contacted by the composition; and (c) removing the composition from the skin wherein residual benzoyl peroxide remains on the skin in an anti-acne effective amount. There are also anti-acne compositions.
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9 +/- 0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9 +/- 0.2% hydroxypropoxylated.
A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated.
Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
40.
MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
(1) Non-medicated preparations containing hyaluronic acid for soft tissue augmentation, and smoothing out facial wrinkles and lines; pharmaceutical preparations, namely, medicated and non-medicated preparations containing hyaluronic acid for use in augmentation of soft tissue and smoothing out fine lines and wrinkles, pharmaceutical preparations containing hyaluronic acid for smoothing out wrinkles and lines, and contouring the lips and face; pharmaceutical preparations namely botulinum toxin and fragments or derivatives of botulinum toxin; kits consisting of syringes prefilled with medicated and non-medicated preparations containing hyaluronic acid for soft tissue augmentation, smoothing out wrinkles and lines, and contouring the lips and face; and dermal fillers. (1) Providing medical education classes and seminars in the field of aesthetic enhancement and aesthetic dermatology.
44.
METHOD OF TREATING PEDIATRIC PATIENTS WITH CORTICOSTEROIDS
The present invention comprises a method of treating pediatric patients suffering from an inflammatory or pruritic skin disorder comprising topically applying fluocinonide to an affected area. Treatment according to this method does not result in clinically significant suppression of the HPA-axis.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
(1) Educational services, namely, conducting seminars, workshops, and classes in the fields of dermatology and aesthetic dermatology, and pharmaceutical product sales; providing educational services in the fields of dermatology and aesthetic dermatology, and pharmaceutical product sales, all rendered through distance learning vehicles.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
pharmaceutical preparations for dermatologic use, namely, topical preparations for the treatment of acne and topical preparations for the treatment of steroid-responsive dermatoses, excluding preparations for the treatment, or alleviation of viral infections, regardless of their dosage form
47.
ZIANA (CLINDAMYCIN PHOSPHATE 1.2% AND TRETINOIN 0.025%) GEL
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
pharmaceutical preparations for dermatologic use, namely, topical preparations for the treatment of acne and topical preparations for the treatment of steroid-responsive dermatoses, excluding preparations for the treatment, or alleviation of viral infections, regardless of their dosage form
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceutical, veterinary and sanitary preparations, excluding ophthalmologic preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles, excluding orthopaedic shoes; suture materials; injectable medical devices; implantable medical devices.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for the treatment of skin conditions; pharmaceutical preparations and substances for the treatment of seborrheic dermatitus; pharmaceutical preparations and substances for the treatment for skin diseases like allergic and topic dermatitis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for dermatologic use, namely topical preparations for the treatment of acne and topical preparations for the treatment of steroid-responsive dermatoses, excluding preparations for the treatment, or alleviation of viral infections, regardless of their dosage form.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, dermatological preparations, medicated skin care preparations, anti-acne preparations, antibiotic preparations, anti fungal preparations, anti-infective preparations, corticosteroid preparations, medicated shampoos, preparations for the treatment of inflammatory skin disorders, preparations for treatment of pediculosis, preparations for the treatment of rosacea, and preparations for the treatment of pigmentation disorders, uneven pigmentation and actinic aging; preparations for the treatment of respiratory, endocrine, rheumatic, collagen, allergic, ophtalmic, hematologic, neoplastic, and gastrointestinal diseases and disorders; preparations for the treatment of bacterial infections; preparations for the treatment of warts; and nasal spray.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
pharmaceutical preparations for dermatologic use, namely, topical preparations for the treatment of acne and topical preparations for the treatment of steroid-responsive dermatoses, excluding preparations for the treatment, or alleviation of viral infections, regardless of their dosage form
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
(1) Full line of dermatological preparations, namely, pharmaceutical preparations, namely antipruritic preparations, analgesic preparations, corticosteroid preparations, wart removal preparations, medicated shampoos, preparations for treating skin discoloration, hyperpigmentation and actinic aging, preparations for treatment of acne, antibiotic preparations, preparations for treatment of pediculosis, and preparations for treatment of hyperammonemia. (1) Arranging and conducting educational conferences in the field of dermatology.
